This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): Mitumomab, IMC-BEC2
Description: BEC2 stimulates the ganglioside GD3 which, in turn, has the potential to stimulate an immune response against tumor cells expressing GD3.BEC2-mediated cancer immunotherapy was stimulated by a manuscript published in the July 1991 issue of the Journal of Clinical Investigation in which Memorial Sloan-Kettering Cancer Center researchers successfully targeted GD3 with BEC2 in rabbit models, stimulating a biologically relevant immune response. Such a tumor vaccine approach is designed to prevent or delay tumor recurrences.
Deal Structure: Merck KGaA and ImClone partnered in 1990 to develop BEC2. ImClone and Merck KGaA will co-promote BEC2 in the U.S. while Merck KGaA has all rights outside the U.S.
In November 2008 Eli Lilly completed the acquisition of ImClone Systems.
Partners: Merck KGaA
Additional information available to subscribers only: